A special dialogue brought together dermatologists, psychotherapists and parents of young patients in Shanghai to discuss skin health and empowerment in children and adolescents, calling for comprehensive scientific intervention and psychological support.
The event was held ahead of the China Derma Care Day, or the National Skin Care Day, which is an annual observance celebrated on May 25 to promote scientific skincare, medical aesthetics, and skin health awareness.
Zhao Xiaoqing, deputy director of the Department of Dermatology at Ruijin Hospital, said if the itchy conditions are not treated promptly and appropriately, persistent severe itching and recurring skin lesions will not only affect a child’s sleep, learning and social life, but may also lead to psychological issues such as low self-esteem and anxiety, and could even result in irreversible, lifelong damage.
He also added that innovative biologics can precisely target the key drivers of Type 2 inflammation, thereby intervening in the disease process and ultimately offering the prospect of long-term remission.
A mini documentary was also unveiled, which shows many cases where patients suffer from difficulties in school and interpersonal relationships due to skin problems, which can be detrimental to their physical and mental health.
It portrays the challenges and transformations experienced by those with atopic dermatitis at different stages of their development, from infancy and early childhood through to school age and adolescence.
Niu Xiaona, a therapist at the Shanghai Mental Health Center, said that safeguarding the mental health of children with atopic dermatitis is by no means a struggle that families must face alone; it requires the collective support of the wider community.
“Only by joining forces to build a sustainable support system can we truly break the shackles of the disease, allowing every child to regain confidence and grow freely in the sunshine,” she noted.
Ji Xian, General Manager of Sanofi China Specialty Care, said the company will continue to work with all stakeholders to drive innovation and accessibility in treatments for AD, and to promote the standardised treatment and comprehensive management of immune-mediated inflammatory conditions.
